These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
318 related articles for article (PubMed ID: 19241120)
21. Closing the door on flaviviruses: entry as a target for antiviral drug design. Perera R; Khaliq M; Kuhn RJ Antiviral Res; 2008 Oct; 80(1):11-22. PubMed ID: 18585795 [TBL] [Abstract][Full Text] [Related]
22. Conformational and energy evaluations of novel peptides binding to dengue virus envelope protein. Amir-Hassan A; Lee VS; Baharuddin A; Othman S; Xu Y; Huang M; Yusof R; Rahman NA; Othman R J Mol Graph Model; 2017 Jun; 74():273-287. PubMed ID: 28458006 [TBL] [Abstract][Full Text] [Related]
23. Virtual screening of eighteen million compounds against dengue virus: Combined molecular docking and molecular dynamics simulations study. Mirza SB; Salmas RE; Fatmi MQ; Durdagi S J Mol Graph Model; 2016 May; 66():99-107. PubMed ID: 27054972 [TBL] [Abstract][Full Text] [Related]
24. Receptor-Guided De Novo Design of Dengue Envelope Protein Inhibitors. Desai VH; Kumar SP; Pandya HA; Solanki HA Appl Biochem Biotechnol; 2015 Oct; 177(4):861-78. PubMed ID: 26299376 [TBL] [Abstract][Full Text] [Related]
25. Extensive structural change of the envelope protein of dengue virus induced by a tuned ionic strength: conformational and energetic analyses. Degrève L; Fuzo CA; Caliri A J Comput Aided Mol Des; 2012 Dec; 26(12):1311-25. PubMed ID: 23160852 [TBL] [Abstract][Full Text] [Related]
26. A Virion-Based Assay for Glycoprotein Thermostability Reveals Key Determinants of Filovirus Entry and Its Inhibition. Bortz RH; Wong AC; Grodus MG; Recht HS; Pulanco MC; Lasso G; Anthony SJ; Mittler E; Jangra RK; Chandran K J Virol; 2020 Aug; 94(18):. PubMed ID: 32611759 [TBL] [Abstract][Full Text] [Related]
27. Structure-based discovery of antiviral inhibitors targeting the E dimer interface of Japanese encephalitis virus. Ye C; Bian P; Zhang J; Xiao H; Zhang L; Ye W; Dong Y; Zhou Y; Jia Z; Lei Y Biochem Biophys Res Commun; 2019 Jul; 515(2):366-371. PubMed ID: 31155294 [TBL] [Abstract][Full Text] [Related]
28. Discovery of novel dengue virus entry inhibitors via a structure-based approach. Leal ES; Aucar MG; Gebhard LG; Iglesias NG; Pascual MJ; Casal JJ; Gamarnik AV; Cavasotto CN; Bollini M Bioorg Med Chem Lett; 2017 Aug; 27(16):3851-3855. PubMed ID: 28668194 [TBL] [Abstract][Full Text] [Related]
29. Towards the design of antiviral inhibitors against flaviviruses: the case for the multifunctional NS3 protein from Dengue virus as a target. Lescar J; Luo D; Xu T; Sampath A; Lim SP; Canard B; Vasudevan SG Antiviral Res; 2008 Nov; 80(2):94-101. PubMed ID: 18674567 [TBL] [Abstract][Full Text] [Related]
30. Structure-based screening and validation of potential dengue virus inhibitors through classical and QM/MM affinity estimation. Ahmed M; Kumar A; Hobman TC; Barakat K J Mol Graph Model; 2019 Jul; 90():128-143. PubMed ID: 31082639 [TBL] [Abstract][Full Text] [Related]
31. In silico design of peptide inhibitors for Dengue virus to treat Dengue virus-associated infections. Ajmal A; Shahab M; Waqas M; Zheng G; Zulfat M; Bin Jardan YA; Wondmie GF; Bourhia M; Ali I Sci Rep; 2024 Jun; 14(1):13130. PubMed ID: 38849372 [TBL] [Abstract][Full Text] [Related]
32. A novel flavivirus entry inhibitor, BP34610, discovered through high-throughput screening with dengue reporter viruses. Yang CC; Hu HS; Lin HM; Wu PS; Wu RH; Tian JN; Wu SH; Tsou LK; Song JS; Chen HW; Chern JH; Chen CT; Yueh A Antiviral Res; 2019 Dec; 172():104636. PubMed ID: 31654671 [TBL] [Abstract][Full Text] [Related]
33. Peptide inhibitors of flavivirus entry derived from the E protein stem. Schmidt AG; Yang PL; Harrison SC J Virol; 2010 Dec; 84(24):12549-54. PubMed ID: 20881042 [TBL] [Abstract][Full Text] [Related]
34. Residues in domain III of the dengue virus envelope glycoprotein involved in cell-surface glycosaminoglycan binding. Watterson D; Kobe B; Young PR J Gen Virol; 2012 Jan; 93(Pt 1):72-82. PubMed ID: 21957126 [TBL] [Abstract][Full Text] [Related]
35. Structure-based drug design for envelope protein E2 uncovers a new class of bovine viral diarrhea inhibitors that block virus entry. Pascual MJ; Merwaiss F; Leal E; Quintana ME; Capozzo AV; Cavasotto CN; Bollini M; Alvarez DE Antiviral Res; 2018 Jan; 149():179-190. PubMed ID: 29031833 [TBL] [Abstract][Full Text] [Related]
36. The Antimalarial Compound Atovaquone Inhibits Zika and Dengue Virus Infection by Blocking E Protein-Mediated Membrane Fusion. Yamamoto M; Ichinohe T; Watanabe A; Kobayashi A; Zhang R; Song J; Kawaguchi Y; Matsuda Z; Inoue JI Viruses; 2020 Dec; 12(12):. PubMed ID: 33371476 [TBL] [Abstract][Full Text] [Related]
37. A ligand-binding pocket in the dengue virus envelope glycoprotein. Modis Y; Ogata S; Clements D; Harrison SC Proc Natl Acad Sci U S A; 2003 Jun; 100(12):6986-91. PubMed ID: 12759475 [TBL] [Abstract][Full Text] [Related]
38. Dengue structural proteins as antiviral drug targets: Current status in the drug discovery & development. S AH; Pujar GV; Sethu AK; Bhagyalalitha M; Singh M Eur J Med Chem; 2021 Oct; 221():113527. PubMed ID: 34020338 [TBL] [Abstract][Full Text] [Related]
39. Geraniin extracted from the rind of Nephelium lappaceum binds to dengue virus type-2 envelope protein and inhibits early stage of virus replication. Abdul Ahmad SA; Palanisamy UD; Tejo BA; Chew MF; Tham HW; Syed Hassan S Virol J; 2017 Nov; 14(1):229. PubMed ID: 29162124 [TBL] [Abstract][Full Text] [Related]
40. Design, synthesis, and biological evaluation of antiviral agents targeting flavivirus envelope proteins. Li Z; Khaliq M; Zhou Z; Post CB; Kuhn RJ; Cushman M J Med Chem; 2008 Aug; 51(15):4660-71. PubMed ID: 18610998 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]